Go to:
Logótipo
You are here: Start > Publications > View > Cyclophosphamide metabolites 4-hydroxycyclophosphamide and acrolein exert strenuous cardiotoxicity in AC16 human cardiomyocytes, at clinical relevant concentrations
Concurso de Escrita Criativa da FEUP
Publication

Cyclophosphamide metabolites 4-hydroxycyclophosphamide and acrolein exert strenuous cardiotoxicity in AC16 human cardiomyocytes, at clinical relevant concentrations

Title
Cyclophosphamide metabolites 4-hydroxycyclophosphamide and acrolein exert strenuous cardiotoxicity in AC16 human cardiomyocytes, at clinical relevant concentrations
Type
Other Publications
Year
2019
Authors
Dionisio, F
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Margarida Araújo
(Author)
ICBAS
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Bastos, MDL
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Felix Carvalho
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Costa, VM
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Other information
Authenticus ID: P-00R-2JJ
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Recommend this page Top
Copyright 1996-2024 © Faculdade de Engenharia da Universidade do Porto  I Terms and Conditions  I Accessibility  I Index A-Z  I Guest Book
Page generated on: 2024-10-01 at 14:56:58 | Acceptable Use Policy | Data Protection Policy | Complaint Portal